Reviva Pharmaceuticals Holdings, Inc. (RVPH)Healthcare | Biotechnology | Cupertino, United States | OTC Markets OTCQB
0.59 USD
-0.03
(-4.355%) ⇩
(July 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 5:27 a.m. EDT
The fundamental reality here is stark: the business is in freefall. Over the last four years, the stock has lost over 91% of its value, driven by a brutal sequence where three out of four annual periods saw double-digit percentage declines. This isn't a temporary dip; it is a structural deterioration confirmed by the market. The company is burning through cash, reporting massive losses, and has been forced off the major exchange to the OTC market—a death knell for liquidity and institutional interest. While the 1-for-20 reverse split is a cosmetic maneuver to prop up the share price, it cannot fix the broken engine. The analyst consensus of 'strong buy' with a $17.50 target is a dangerous illusion based on outdated models that ignore the reality of the delisting and the relentless price decay. There is no safety margin here, only a value trap waiting to trap the unwary. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.351102 |
| AutoETS | 0.365735 |
| AutoARIMA | 0.604384 |
| AutoTheta | 0.622619 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 30% |
| H-stat | 0.28 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.133 |
| Excess Kurtosis | -0.90 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 1.326 |
| Market Cap | 7,774,453 |
| Forward P/E | -0.31 |
| Beta | 0.47 |
| Website | https://www.revivapharma.com |
As of July 11, 2026, 5:27 a.m. EDT: Speculators are positioning for a continued grind lower rather than a rebound. Put open interest is heavily concentrated at strikes significantly above the current price (1.5 and 2.0), creating a 'pinning' effect that suggests traders expect the stock to struggle to break these psychological barriers. Call activity is sparse and skewed toward lower strikes, indicating a lack of aggressive bullish sentiment despite the low absolute price.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.92778945 |
| Address1 | 10,080 N. Wolfe Road |
| Address2 | Suite SW3-200 |
| All Time High | 192.2 |
| All Time Low | 0.262 |
| Ask | 0.6199 |
| Ask Size | 3,000 |
| Average Daily Volume10 Day | 61,060 |
| Average Daily Volume3 Month | 447,163 |
| Average Volume | 447,163 |
| Average Volume10Days | 61,060 |
| Beta | 0.47 |
| Bid | 0.593 |
| Bid Size | 8,480 |
| Book Value | 1.361 |
| City | Cupertino |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.593 |
| Current Ratio | 3.85 |
| Custom Price Alert Confidence | LOW |
| Date Short Interest | 1,777,507,200 |
| Day High | 0.62 |
| Day Low | 0.585 |
| Debt To Equity | 1.326 |
| Display Name | Reviva Pharmaceuticals |
| Earnings Timestamp End | 1,786,651,200 |
| Earnings Timestamp Start | 1,786,651,200 |
| Ebitda Margins | 0.0 |
| Enterprise Value | -14,184,503 |
| Eps Current Year | -1.6 |
| Eps Forward | -1.9 |
| Eps Trailing Twelve Months | -3.19 |
| Esg Populated | 0 |
| Exchange | OQB |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 408 904 6270 |
| Fifty Day Average | 0.6063536 |
| Fifty Day Average Change | -0.013353586 |
| Fifty Day Average Change Percent | -0.02202277 |
| Fifty Two Week Change Percent | -92.778946 |
| Fifty Two Week High | 17.2 |
| Fifty Two Week High Change | -16.607 |
| Fifty Two Week High Change Percent | -0.96552324 |
| Fifty Two Week Low | 0.262 |
| Fifty Two Week Low Change | 0.331 |
| Fifty Two Week Low Change Percent | 1.2633588 |
| Fifty Two Week Range | 0.262 - 17.2 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,608,042,600,000 |
| Float Shares | 11,378,365 |
| Forward Eps | -1.9 |
| Forward P E | -0.31210527 |
| Free Cashflow | -14,494,285 |
| Full Exchange Name | OTC Markets OTCQB |
| Full Time Employees | 14 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 0 |
| Held Percent Insiders | 0.07727 |
| Held Percent Institutions | 0.12784 |
| Implied Shares Outstanding | 13,110,377 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,773,014,400 |
| Last Split Factor | 1:20 |
| Long Business Summary | Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications, such as schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis. It also engages in the clinical development for respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis. In addition, the company is in preclinical development for the treatment of psoriasis; and RP1208 for the treatment of depression and obesity. The company was founded in 2018 and is headquartered in Cupertino, California. |
| Long Name | Reviva Pharmaceuticals Holdings, Inc. |
| Market | us_market |
| Market Cap | 7,774,453 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_126911636 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -16,628,049 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 8,128,433 |
| Number Of Analyst Opinions | 2 |
| Open | 0.62 |
| Operating Cashflow | -20,201,740 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 408 501 8881 |
| Previous Close | 0.62 |
| Price Eps Current Year | -0.370625 |
| Price Hint | 4 |
| Price To Book | 0.43570906 |
| Profit Margins | 0.0 |
| Quick Ratio | 3.626 |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.02700001 |
| Regular Market Change Percent | -4.3548403 |
| Regular Market Day High | 0.62 |
| Regular Market Day Low | 0.585 |
| Regular Market Day Range | 0.585 - 0.62 |
| Regular Market Open | 0.62 |
| Regular Market Previous Close | 0.62 |
| Regular Market Price | 0.593 |
| Regular Market Time | 1,783,972,800 |
| Regular Market Volume | 15,663 |
| Return On Assets | -0.69091004 |
| Return On Equity | -2.5620098 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 13,110,377 |
| Shares Percent Shares Out | 0.1457 |
| Shares Short | 1,866,151 |
| Shares Short Previous Month Date | 1,774,915,200 |
| Shares Short Prior Month | 1,834,224 |
| Short Name | Reviva Pharmaceuticals Holdings |
| Short Percent Of Float | 0.1495 |
| Short Ratio | 3.35 |
| Source Interval | 15 |
| State | CA |
| Symbol | RVPH |
| Target High Price | 30.0 |
| Target Low Price | 5.0 |
| Target Mean Price | 17.5 |
| Target Median Price | 17.5 |
| Total Cash | 22,190,232 |
| Total Cash Per Share | 1.693 |
| Total Debt | 231,274 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -3.19 |
| Trailing Peg Ratio | None |
| Triggerable | 0 |
| Two Hundred Day Average | 5.2254515 |
| Two Hundred Day Average Change | -4.6324515 |
| Two Hundred Day Average Change Percent | -0.886517 |
| Type Disp | Equity |
| Volume | 15,663 |
| Website | https://www.revivapharma.com |
| Zip | 95,014 |